As reported by The Pharma Times, Roche’s cancer drug, Avastin, helped patients suffering with newly diagnosed brain cancer to live longer in a late stage study.
Results from the Phase III study indicated that when combined with radiation and temozolomide chemotherapy, Avastin reduced the risk of the cancer worsening or of death by 36 per cent (compared to those patients who received radiation and temozolomide plus a placebo). However, the drug did not reach statistical significance.
The chief medical officer and head of Global Product Development at Roche, Hall Barron M.D, stated, “People with newly diagnosed glioblastoma have few treatment options and need new medicines. An important outcome from the AVAglio study was that patients who received Avastin plus radiation and chemotherapy lived significantly longer without their disease getting worse, and we plan to discuss these data with regulatory authorities.”
Avastin is the Swiss pharmaceutical company’s third-biggest seller and is approved to treat several types of cancer, including breast, kidney, colorectal and ovarian cancers.
Are you looking for a new position in the pharmaceutical industry?